Display options
Cite
Goulart BHL, Chennupati S, Fedorenko CR, et al. Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR. Clin Lung Cancer. 2021;22(5):e723-e733doi: 10.1016/j.cllc.2021.01.019.
Goulart, B. H. L., Chennupati, S., Fedorenko, C. R., & Ramsey, S. D. (2021). Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR. Clinical lung cancer, 22(5), e723-e733. https://doi.org/10.1016/j.cllc.2021.01.019
Goulart, Bernardo H L, et al. "Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR." Clinical lung cancer vol. 22,5 (2021): e723-e733. doi: https://doi.org/10.1016/j.cllc.2021.01.019
Goulart BHL, Chennupati S, Fedorenko CR, Ramsey SD. Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR. Clin Lung Cancer. 2021 Sep;22(5):e723-e733. doi: 10.1016/j.cllc.2021.01.019. Epub 2021 Feb 04. PMID: 33685820.
Copy Download .nbib Format: NLM
Share it on

Clin Lung Cancer. 2021 Sep;22(5):e723-e733. doi: 10.1016/j.cllc.2021.01.019. Epub 2021 Feb 04.

Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR.

Clinical lung cancer

Bernardo H L Goulart, Shasank Chennupati, Catherine R Fedorenko, Scott D Ramsey

Affiliations

  1. Fred Hutchinson Cancer Research Center, Seattle, WA; Hutchinson Institute for Cancer Outcomes Research (HICOR), Seattle, WA. Electronic address: [email protected].
  2. Fred Hutchinson Cancer Research Center, Seattle, WA; Hutchinson Institute for Cancer Outcomes Research (HICOR), Seattle, WA.
  3. Fred Hutchinson Cancer Research Center, Seattle, WA; Hutchinson Institute for Cancer Outcomes Research (HICOR), Seattle, WA; University of Washington Medical Center, Seattle, WA.

PMID: 33685820 DOI: 10.1016/j.cllc.2021.01.019

Abstract

INTRODUCTION: We assessed the proportion of patients with advanced epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) who receive tyrosine kinase inhibitors (TKIs) in the real-world, predictors of TKI use, and impact of TKI therapy on overall survival (OS).

MATERIALS AND METHODS: We identified patients diagnosed with stage IV EGFR

RESULTS: Of 117 eligible patients (median age = 69; 62% women; 88% EGFR

CONCLUSION: Approximately 18% of patients with advanced EGFR

Copyright © 2021. Published by Elsevier Inc.

Keywords: Barriers; Care delivery; Outcomes; TKIs; Targed therapy

Publication Types